CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26429979.
- Also identified by DOI 10.1158/1078-0432.CCR-15-1381.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Vredenburgh and colleagues conducted the first phase II study of bevacizumab plus irinotecan in recurrent malignant glioma, confirming the safety and efficacy of bevacizumab. This study, which was published in the February 15, 2007, issue of Clinical Cancer Research, was a stepping stone for subsequent research, leading to regulatory approval of bevacizumab for recurrent glioblastoma.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Brain Neoplasms
- Glioma
- Neoplasm Recurrence, Local